Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if CYTK is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
90 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 1 days ago
Red flags: 31
482 filers reported a long position in CYTK for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $1.7B | 20.1M | +21.4% |
| T. Rowe Price Investment Management, Inc. | $1.6B | 18.7M | +6.8% |
| WELLINGTON MANAGEMENT GROUP LLP | $590.5M | 6.9M | -13.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.8M | 6.7M | +14.9% |
| STATE STREET CORP | $553.2M | 6.5M | +13% |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.2M | 6.1M | +11.5% |
| FMR LLC | $428.7M | 5M | -53.1% |
| Avoro Capital Advisors LLC | $425.9M | 5M | +50% |
| BANK OF AMERICA CORP /DE/ | $394.9M | 4.6M | +48.3% |
| GEODE CAPITAL MANAGEMENT, LLC | $316.3M | 3.7M | +15.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.